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Problem Definition
• The Jefferson Department of Urology is a high-volume 
clinic that performs hundreds of prostate biopsies 
annually
• Although the overall risk of the procedure is low, the rate 
of infectious complications have increased
• The American Urologic Association (AUA) recommends 
antibiotic prophylaxis pathways to prevent infections
• We assessed differences in the risk of infectious 
complications based on the prophylaxis pathway, using 
data from the Pennsylvania Urologic Regional 
Collaborative (PURC)
Aims For Improvement
• The aim of this study was to determine the antibiotic 
prophylaxis associated with the fewest infectious 
complications following prostate biopsy
• Determining the safest method allows the Jefferson 
Department of Urology to modify its biopsy protocol and 
improve the rate of post-biopsy complications
Methods
• A total of 11,896 biopsies since 2015 were analyzed for:
• PBx Prophylaxis Pathway
• Demographics and  PBx Outcomes
• Infectious outcomes included a fever, UTI or sepsis
• Univariate and multivariate analysis determined factors 
associated with infections
Measurement and Results
Table 1: Demographic and Patient Characteristics
Next Steps and Lessons Learned
• A targeted antibiotic prophylaxis pathway significantly 
reduced the risk of infectious complications compared to 
the augmented or provider discretion pathways
• This study achieved the aim to determine the safest 
prophylaxis method
• Next steps should include standardization and 
modification of the Jefferson Urology prostate biopsy 
protocol to include culture- based prophylaxis
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Culture-
Directed
Augmented
Provider 
Discretion
Prophylaxis 
Pathways
Abx based on 
rectal swab
Baseline abx 
+ 2nd from 
antibiogram
Abx based on 
physician 
judgment
Variables OR [95% CI] P-value
Age > 80 years 1.091 [0.470-2.536] 0.839
Number of Previous Biopsies
1 Biopsy vs. No Previous Biopsy 1.456 [0.868-2.442] 0.155
>1 Previous Biopsy vs. No Previous 
Biopsy
2.184 [1.226-3.888] 0.008a
Gland Volume (10g or cc) 1.054 [1.008-1.103] 0.022a
Histology, Others vs. 
Adenocarcinoma
4.247 [0.831-21.696] 0.086a
Biopsy Type 
TURP vs. TRUS 3.426 [1.860-6.313] <0.001a
MRI/Fusion vs. TRUS 1.684 [1.043-2.719] 0.033a
Antibiotic Prophylaxis Pathway
Culture-Directed vs. Provider 
Discretion
0.149 [0.069-0.321] <0.001a
Augmented vs. Provider Discretion 1.019 [0.635-1.634] 0.939
Comorbidities
BMI 1.007 [0.969-1.048] 0.713
Peripheral Vascular Disease 1.090 [0.222-5.358] 0.916
Diabetes 1.312 [0.795-2.164] 0.288
Cerebral Vascular Disease 1.017 [0.360-2.874] 0.974
2nd Solid Tumor 1.191 [0.438-3.245] 0.732
Chronic Kidney Disease (Cr>3) 1.084 [0.185-6.332] 0.929
aSignificance level for univariate analyses was set at 0.10; variables 
meeting this significance were utilized for multivariate analysis
• More than 1 previous biopsy, type of biopsy and prophylaxis pathway 
were significantly associated with infectious outcome
• No comorbidities were associated with greater risk of infection
Characteristic n(%) Culture-
Directed 
(N=3246)
Augmented 
(N=1443)
No Pathway 
(N=7207)
Age > 80 years 52 (2.9) 20 (3.3) 257 (6.8)
1 Previous Biopsy 140 (4.5) 220 (17.2) 786 (12.8)
More than 1 Previous 
Biopsy
105 (3.4) 110 (8.6) 335 (5.4)
Infectious Outcome 7 (0.2) 20 (1.4) 95 (1.3)
Table 2: Univariate Analysis for Predictors of Infectious 
Outcomes
Variables OR [95% CI] P-value
Antibiotic Prophylaxis
Pathway
Culture-Directed vs. Provider 
Discretion
0.159 [0.074-0.344] <0.001a
Augmented vs. Provider 
Discretion
1.014 [0.630-1.633] 0.953
Biopsy Type
TURP vs. TRUS 2.838 [1.536-5.242] 0.001a
MRI/Fusion vs. TRUS 1.416 [0.874-2.294] 0.158
aSignificance level for multivariate analyses was set at 
0.05
• Culture-directed pathway was associated with a 84% 
reduction in infectious outcomes compared to provider 
discretion or the augmented pathways
• Biopsy during TURP was significantly associated with 
infections compared to TRUS
Table 3: Multivariate Analysis for Predictors of 
Infectious Outcomes
1. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, 
Pennsylvania
2. Health Care Improvement Foundation, Philadelphia, Pennsylvania
3. Geisinger Medical Center, Danville, Pennsylvania
4. Einstein Healthcare Network, Philadelphia, Pennsylvania
5. University of Pennsylvania, Philadelphia, Pennsylvania
6. Midlantic Urology, Philadelphia, Pennsylvania
7. Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
8. Fox Chase Cancer Center, Philadelphia, Pennsylvania
9. Cooper University, Camden, New Jersey
10.Temple University, Philadelphia, Pennsylvania
Author Affiliations 
